| 基于PD-1/PD-L1靶点的肿瘤免疫治疗研究进展 |
| |
| 引用本文： | 卢哲,张国军,姚群峰.基于PD-1/PD-L1靶点的肿瘤免疫治疗研究进展[J].现代肿瘤医学,2022,0(5):926-930. |
| |
| 作者姓名： | 卢哲 张国军 姚群峰 |
| |
| 作者单位： | 湖北中医药大学检验学院，湖北 武汉 430065 |
| |
| 基金项目： | 国家自然科学基金资助项目(编号:21974035)。 |
| |
| 摘 要： | 近年来的研究显示,肿瘤免疫治疗在恶性肿瘤的治疗上成效显著,疗效优于传统的化疗和放疗.程序性死亡受体-1(programmed death 1,PD-1)和程序性死亡受体配体-1(programmed death-ligand 1,PD-L1)这对免疫共抑制分子作为肿瘤免疫治疗的靶点备受关注,PD-L1在一些肿瘤细胞中的...
|
| 关 键 词： | 肿瘤 免疫治疗 PD-1 PD-L1 |
The progress in cancer immunotherapy targeting PD-1/PD-L1 immune checkpoint |
| |
| LU Zhe,ZHANG Guojun,YAO Qunfeng.The progress in cancer immunotherapy targeting PD-1/PD-L1 immune checkpoint[J].Journal of Modern Oncology,2022,0(5):926-930. |
| |
| Authors: | LU Zhe ZHANG Guojun YAO Qunfeng |
| |
| Institution: | School of Laboratory Medicine,Hubei University of Chinese Medicine,Hubei Wuhan 430065,China. |
| |
| Abstract: | Recently, cancer immunotherapy has achieved great progress in malignant tumors, outperforming traditional chemotherapy and radiotherapy.Programmed death 1(PD-1)and programmed death-ligand 1(PD-L1),this two co-suppressing molecules as the target for cancer immunotherapy, is under the spotlight.The up-expression of PD-L1 on some tumor cells down-regulate immune activity, suppressing the tumor-killing function of CD8;T cells and anti-tumor immunity of the body.The methods for cancer immunotherapy targeting PD-1/PD-L1 mainly include immune checkpoint inhibitor treatment, chimeric antigen receptor-T cells treatment and gene-editing treatment, etc.This review sheds light on the methods for cancer immunotherapy and the progress of gene-engineering treatment and nanomedicine-based treatment. |
| |
| Keywords: | neoplasm immunotherapy PD-1 PD-L1 |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
| 点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
|
